198 related articles for article (PubMed ID: 20371467)
21. Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.
Tsegaye TS; Butler K; Luo W; Radzio J; Srinivasan P; Sharma S; Aubert RD; Hanson DL; Dobard C; Garcia-Lerma JG; Heneine W; McNicholl JM; Kersh EN
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):385-94. PubMed ID: 25886925
[TBL] [Abstract][Full Text] [Related]
22. Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis.
Kersh EN; Luo W; Zheng Q; Adams DR; Hanson D; Youngpairoj AS; Cong ME; Butler K; Hendry RM; McNicholl JM; Heneine W; Garcia-Lerma JG
J Infect Dis; 2012 Sep; 206(5):770-9. PubMed ID: 22740713
[TBL] [Abstract][Full Text] [Related]
23. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
[TBL] [Abstract][Full Text] [Related]
24. Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis.
Zheng Q; Ruone S; Switzer WM; Heneine W; García-Lerma JG
Retrovirology; 2012 May; 9():40. PubMed ID: 22571771
[TBL] [Abstract][Full Text] [Related]
25. Animal models of antiretroviral prophylaxis for HIV prevention.
García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2012 Nov; 7(6):505-13. PubMed ID: 22964889
[TBL] [Abstract][Full Text] [Related]
26. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis.
Curtis KA; Kennedy MS; Luckay A; Cong ME; Youngpairoj AS; Zheng Q; Smith J; Hanson D; Heneine W; Owen SM; García-Lerma JG
J Acquir Immune Defic Syndr; 2011 Aug; 57(5):355-62. PubMed ID: 21637113
[TBL] [Abstract][Full Text] [Related]
27. Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs.
Cong ME; Pau CP; Heneine W; García-Lerma JG
PLoS One; 2016; 11(11):e0164821. PubMed ID: 27806064
[TBL] [Abstract][Full Text] [Related]
28. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Dominguez S; Ghosn J; Peytavin G; Izzedine H; Wirden M; Ktorza N; Miller M; Aubron-Olivier C; Trylesinski A; Calvez V; Deray G; Katlama C
J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308
[TBL] [Abstract][Full Text] [Related]
30. Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment.
Spring M; Stahl-Hennig C; Stolte N; Bischofberger N; Heeney J; ten Haaft P ; Tenner-Ràcz K; Ràcz P; Lorenzen D; Hunsmann G; Dittmer U
Virology; 2001 Jan; 279(1):221-32. PubMed ID: 11145904
[TBL] [Abstract][Full Text] [Related]
31. Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques.
Cong ME; Youngpairoj AS; Aung W; Sharma S; Mitchell J; Dobard C; Heneine W; Garcia-Lerma JG
Virology; 2011 Apr; 412(2):435-40. PubMed ID: 21334708
[TBL] [Abstract][Full Text] [Related]
32. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
[TBL] [Abstract][Full Text] [Related]
33. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
Kumar A; Buch S; Foresman L; Bischofberger N; Lifson JD; Narayan O
Virology; 2001 Jan; 279(1):97-108. PubMed ID: 11145893
[TBL] [Abstract][Full Text] [Related]
34. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
[TBL] [Abstract][Full Text] [Related]
35. Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir.
Bourry O; Brochard P; Souquiere S; Makuwa M; Calvo J; Dereudre-Bosquet N; Martinon F; Benech H; Kazanji M; Le Grand R
AIDS; 2009 Feb; 23(4):447-54. PubMed ID: 19240457
[TBL] [Abstract][Full Text] [Related]
36. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
Blum MR; Chittick GE; Begley JA; Zong J
J Clin Pharmacol; 2007 Jun; 47(6):751-9. PubMed ID: 17519400
[TBL] [Abstract][Full Text] [Related]
37. Double oral administration of emtricitabine/tenofovir prior to virus exposure protects against highly pathogenic simian/human immunodeficiency virus infection in macaques.
Nakasone T; Murakami T; Yamamoto N
Jpn J Infect Dis; 2012 Jul; 65(4):345-9. PubMed ID: 22814162
[TBL] [Abstract][Full Text] [Related]
38. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
De Clercq E
Expert Opin Pharmacother; 2009 Dec; 10(17):2935-7. PubMed ID: 19929712
[TBL] [Abstract][Full Text] [Related]
39. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge.
Radzio J; Spreen W; Yueh YL; Mitchell J; Jenkins L; García-Lerma JG; Heneine W
Sci Transl Med; 2015 Jan; 7(270):270ra5. PubMed ID: 25589631
[TBL] [Abstract][Full Text] [Related]
40. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
